Global cannabis specialist calls for rescheduling of CBD
It's a shame, we are missing something important He said in a speech in Colorado. The professor emeritus praised at the inauguration of the Institute of Cannabis Research in Pueblo, the ingredient in cannabis, CBD. Cannabidiol (CBD), is the non-psychoactive component of cannabis, unlike THC which is psychoactive. CBD is considered a great health benefit. But CBD is still considered a dangerous, first-class substance in the context of the cannabis plant. Yet CBD offers many medical benefits, as it is anti-inflammatory, anti-nausea, and helping to treat sleep disorders. CBD has previously been described by Mechoulam, a professor at Hebrew University for six decades as “ ideal for the treatment of schizophrenia«
Intervention of Professor Mechoulam in favor of the CBD
If the United States stops viewing CBD as an illegal substance, it would unlock the immense potential of marijuana. Already as a drug said the father of cannabis research on Saturday in Pueblo. Indeed, Raphael Mechoulam, the professor and chemist, was in Colorado on Saturday. As keynote speaker at the inaugural of the University of Colorado, theCannabis Research Institute from Pueblo.
“I believe the CBD must come out of this illegal situation. She is classified next to the heroine. Which doesn't make sense, because it's not toxic. Does not cause any addiction, so you have to move it (from annex 1), ”Mechoulam told the The Denver Post in a brief interview following his speech. “And once the substance gets moved, more people will use it. And hopefully it will become a major (medicinal) drug. "
Professor Mechoulam's hour-long speech focused on his research. By offering a vast collection that includes approximately 400 scientific articles cited near 100 000 times. Mechoulam is credited for the discovery of the endocannabinoid system and the isolation, chemical and structural composition, as well as the synthesis of major cannabinoids in cannabis. In particular cannabidiol (CBD), delta-9 tetrahydrocannabinol (THC) and cannabigerol (CBG).
Entourage effect of cannabis
Mechoulam also discussed the “entourage effect”. A concept he helped describe how compounds in cannabis work in harmony. Notably, to potentially produce more effective benefits than they would on their own. He expressed optimism that CSU-Pueblo, through its Cannabis Research Institute, could conduct further research on this theory.
Mechoulam has highlighted some of his team's results over the years. Especially with delta-8 tetrahydrocannabinol which prevents vomiting and other side effects of chemotherapy in children with cancer. In addition, CBD prevented the onset of 1-type diabetes in mice and serves asantipsychotic to patients with schizophrenia.
“The research is there and in some cases it has been around for decades,” he said. “Now it's up to someone to put the results to use and advance the science in medicine. »He added. “It should be done… but unfortunately nothing is happening at the moment,” Mechoulam said.
Professor requests more clinical trials
"Clinical trials are expensive" according to the professor. “And those who live in academia don't have the capacity or the resources to take the next steps,” he said. Adding that he "waited about 10 years" for a pharmaceutical company or other significant entity to conduct a clinical trial on the effectiveness of CBD in prevention and treatment of type 1 diabetes.
"It's a shame because in this particular case, type 1 diabetes is no different… in mice and in humans," he said. “So, we're missing something. I hope one of these days someone will do a clinical trial. And will show, I hope, that type 1 diabetes can be treated with cannabidiol with mainly side effects ”.
United States Narcotics Administration (DEA) officials consider CBD and other marijuana extracts to be Schedule I substances. This is the most stringent of the classifications. However, this purely political position is contested. The newly formed Institute of Cannabis Research's three-day conference drew 550 participants from 10 countries and 21 US states.
Additionally, the event's discussion boards covered a wide range of topics. Such as research, tax, real estate, medicine, health and business. So many arguments that the DEA will have no choice but to take into account.